Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone-Reference-Cited by-同舟云学术

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

Published:2021-03 Issue: Volume:220 Page:108492
ISSN:0376-8716
Container-title:Drug and Alcohol Dependence
language:en
Short-container-title:Drug and Alcohol Dependence

Author:

Rolland Benjamin^ORCID,Trojak Benoit^ORCID,Nourredine Mikail^ORCID,Bachellier Jérôme^ORCID,Chappuy Mathieu^ORCID,Bendimerad Patrick,Kosim Margaux,Hjelmström Peter^ORCID,Meroueh Fadi^ORCID,Nubukpo Philippe,Brousse Georges^ORCID

Funder

Camurus Lipid Research Foundation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Toxicology

Reference21 articles.

1. Medication treatment of opioid use disorder;Bell;Biol. Psychiatry,2019

2. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses;Bi-Mohammed;Drug Alcohol Depend.,2017

3. Health and Social Responses to Drug Problems: a European Guide [internet]. 2017;European Monitoring Centre for Drugs and Drug Addiction,2017

4. Why buprenorphine is so successful in treating opiate addiction in France;Fatseas;Curr. Psychiatry Rep.,2007

5. Policy pathways to address provider workforce barriers to buprenorphine treatment;Haffajee;Am. J. Prev. Med.,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids;Journal of Addiction Medicine;2023-07-28

2. Predictive factors for acceptance of a long-acting opiate substitution treatment studied through social representations and internalized stigma;Therapies;2023-07

3. ‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue;International Journal of Drug Policy;2023-05

4. Factors to guide the use of extended-release buprenorphine formulations for specific patient populations;Journal of Substance Use;2023-02-08

5. Traitements médicamenteux de l’addiction aux opioïdes;Les Addictions;2023